Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-HepB-rPV-Hib vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-rPV-Hib vaccine (SIIPL DTwP-HepB-rPV-Hib) is an investigational, fully liquid hexavalent combination vaccine developed by the Serum Institute of India. It is designed for the active immunization of infants and toddlers against six major childhood infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). Unlike traditional hexavalent vaccines that utilize inactivated poliovirus vaccine (IPV) derived from wild-type or Sabin poliovirus strains, this formulation incorporates a novel recombinant poliomyelitis vaccine (rPV) component. The vaccine is currently being evaluated in Phase I/II clinical trials to assess its safety, reactogenicity, and immunogenicity compared to the licensed HEXASIIL vaccine.
- Other names
- combined diphtheria, tetanus, whole cell pertussis, hepatitis B, recombinant poliomyelitis and Haemophilus influenzae type b vaccinediphtheria, tetanus, whole cell pertussis, hepatitis B, recombinant poliomyelitis and Haemophilus influenzae type b vaccineSIIPL DTwP-HepB-rPV-HibSIIPL DTwP-HepB-rPV-Hib vaccine
02
Targets
Diphtheria toxinPRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)HBsAg (Hepatitis B surface antigen)BCR-PV (B-cell receptor specific for poliovirus capsid epitopes)ETV6 (ETS variant transcription factor 6)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTwP-HepB-rPV-Hib vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-HepB-rPV-Hib vaccine.